KFH - ANTIOCH
- Type
- Teaching hospital
- Where
- ANTIOCH, CA
- Medicare CCN
- 050760
- Received
- $6,769,730 in 440 records, 2019 ($1,326 general, $6,768,403 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 6 | $1,326 |
| 2019 | Research payment | 434 | $6,768,403 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 430 | $6,750,945 | 2019 |
| MEDIVATION LLC. | 5 | $17,531 | 2019 |
| Cochlear Americas | 4 | $1,175 | 2019 |
| Zimmer Biomet Holdings, Inc. | 1 | $78 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 434 | $6,768,403 |
| Grant | 4 | $1,175 |
| Gift | 1 | $78 |
| Travel and Lodging | 1 | $72 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $78 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-23 | PFIZER INC. | $314,744 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | CRCPREDICTORS OF PNEUMOCOCCAL VACCINATION PNEUMOCOCCAL VACCINE EFFECTIVENESS AND TRENDS IN PNEUMONIA | 2019 |
| 2019-12-20 | PFIZER INC. | $2,045 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-12-19 | PFIZER INC. | $6,278 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-12-18 | PFIZER INC. | $30,600 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $20,400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $17,340 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $5,940 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $4,149 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $4,070 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $4,050 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $2,860 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $2,775 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $1,950 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $1,593 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $1,003 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-18 | PFIZER INC. | $885 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $35,700 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $7,260 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $4,950 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $3,149 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $2,035 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $944 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $837 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-12-12 | PFIZER INC. | $837 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-12-12 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-12 | PFIZER INC. | $418 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-12-12 | PFIZER INC. | $418 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-12-11 | PFIZER INC. | $16,830 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-11 | PFIZER INC. | $3,630 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-11 | PFIZER INC. | $2,475 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-11 | PFIZER INC. | $973 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-06 | PFIZER INC. | $9,574 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-12-05 | PFIZER INC. | $2,099 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-05 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-05 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-05 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-12-04 | PFIZER INC. | $3,749 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-11-28 | PFIZER INC. | $16,830 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $4,723 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $3,520 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $3,519 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $2,930 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-11-28 | PFIZER INC. | $2,880 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $2,661 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $2,512 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-11-28 | PFIZER INC. | $2,512 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-11-28 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $1,889 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $1,574 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $1,256 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-11-28 | PFIZER INC. | $737 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-28 | PFIZER INC. | $300 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-27 | MEDIVATION LLC. | $2,965 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE | 2019 |
| 2019-11-27 | MEDIVATION LLC. | $715 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE | 2019 |
| 2019-11-23 | PFIZER INC. | $4,471 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-11-21 | PFIZER INC. | $2,386 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-11-20 | PFIZER INC. | $17,250 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $7,632 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $2,346 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $2,346 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $2,204 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $2,204 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $1,716 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $1,259 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-20 | PFIZER INC. | $314 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-18 | PFIZER INC. | $297,107 | Research payment | Cash or cash equivalent | ZITHROMAX Drug, INFECTIOUS DISEASES | THE ACUTE EFFECTS OF AZITHROMYCIN USE ON CARDIOVASCULAR MORTALITY AS COMPARED WITH AMOXICILLIN | 2019 |
| 2019-11-18 | PFIZER INC. | $37,356 | Research payment | Cash or cash equivalent | ATOPIC DERMATITIS STANDING COHORT USING A COHORT OF KAISER PERMANENTE NORTHERN CALIFORNIA MEMBERS KPNC | 2019 | |
| 2019-11-13 | PFIZER INC. | $16,525 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2019 | |
| 2019-11-13 | PFIZER INC. | $11,818 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $3,291 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $2,976 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $2,877 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $2,574 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $944 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-13 | PFIZER INC. | $629 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-11-02 | PFIZER INC. | $5,451 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-11-01 | PFIZER INC. | $1,363 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-10-30 | PFIZER INC. | $5,559 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-10-30 | PFIZER INC. | $2,830 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-10-30 | PFIZER INC. | $1,992 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-10-30 | PFIZER INC. | $837 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-10-30 | MEDIVATION LLC. | $585 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE | 2019 |
| 2019-10-24 | PFIZER INC. | $13,947 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-10-24 | PFIZER INC. | $12,745 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-10-24 | PFIZER INC. | $9,262 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-10-24 | PFIZER INC. | $5,834 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-10-24 | PFIZER INC. | $5,557 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-10-24 | PFIZER INC. | $4,816 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-10-24 | PFIZER INC. | $3,300 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-10-23 | PFIZER INC. | $13,300 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $9,633 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-10-23 | PFIZER INC. | $8,151 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-10-23 | PFIZER INC. | $7,410 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-10-23 | PFIZER INC. | $6,940 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $4,464 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $4,439 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $4,149 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $3,360 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $2,661 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $2,574 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $700 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-23 | PFIZER INC. | $350 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-22 | PFIZER INC. | $5,000 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-10-22 | PFIZER INC. | $72 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-10-09 | PFIZER INC. | $10,509 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-09 | PFIZER INC. | $4,594 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-09 | PFIZER INC. | $2,951 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-09 | PFIZER INC. | $2,031 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-09 | PFIZER INC. | $1,488 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-09 | PFIZER INC. | $1,488 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-08 | PFIZER INC. | $7,365 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-10-02 | PFIZER INC. | $10,614 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $7,953 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $5,514 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $2,964 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $2,420 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $2,019 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $1,920 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $1,716 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $1,475 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-02 | PFIZER INC. | $200 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-01 | PFIZER INC. | $7,875 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-09-25 | PFIZER INC. | $8,730 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-09-25 | PFIZER INC. | $3,656 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-09-25 | PFIZER INC. | $3,649 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-09-25 | PFIZER INC. | $2,218 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-09-19 | PFIZER INC. | $8,294 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-09-18 | PFIZER INC. | $6,607 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $5,841 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $5,211 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $3,822 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $3,433 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $3,192 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $2,574 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-18 | PFIZER INC. | $1,716 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $15,770 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $14,431 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $12,189 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $7,934 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $6,156 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $5,853 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $4,767 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-11 | PFIZER INC. | $4,594 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-09-04 | PFIZER INC. | $6,068 | Research payment | Cash or cash equivalent | A PHASE 2B3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF06651 | 2019 | |
| 2019-08-28 | PFIZER INC. | $22,032 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $8,188 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $7,657 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $6,712 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $6,298 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-08-28 | PFIZER INC. | $4,594 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $3,334 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-08-28 | PFIZER INC. | $3,180 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $2,877 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $2,223 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJ | 2019 |
| 2019-08-28 | PFIZER INC. | $2,118 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $2,000 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $1,950 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $1,250 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-28 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-27 | PFIZER INC. | $19,091 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-08-21 | PFIZER INC. | $5,223 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-08-21 | PFIZER INC. | $4,712 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-08-21 | PFIZER INC. | $2,218 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-08-21 | PFIZER INC. | $1,431 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-08-16 | PFIZER INC. | $10,466 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-08-14 | PFIZER INC. | $41,051 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $18,247 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $16,388 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $14,634 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $10,954 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $10,787 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $8,768 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $7,799 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-14 | PFIZER INC. | $250 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-08-03 | PFIZER INC. | $33,540 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACC | 2019 |
| 2019-07-24 | PFIZER INC. | $10,571 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $10,522 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $7,521 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $6,360 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $5,509 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-07-24 | PFIZER INC. | $4,680 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $4,668 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $4,068 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-07-24 | PFIZER INC. | $4,038 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-24 | PFIZER INC. | $3,792 | Research payment | Cash or cash equivalent | PREVNAR - 13 Biological, VACCINES | A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2019 |
| 2019-07-24 | PFIZER INC. | $3,192 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 |
The latest 200 records of 440.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.
| Measure | Place (city or town) Antioch, CA | County Contra Costa County, CA | State California |
|---|---|---|---|
| Population B01003 | 116,477 | 1,165,012 | 39,287,377 |
| Population, 2020 census P1 | 115,291 | 1,165,927 | 39,538,223 |
| Median age B01002 | 38.4 | 40.5 | 37.9 |
| Under 18 B01001 | 22.8% | 22.0% | 22.0% |
| 65 and over B01001 | 14.3% | 17.1% | 15.7% |
| Households B11001 | 37,381 | 414,417 | 13,548,091 |
| Foreign born B05002 | 24.6% | 26.6% | 27.0% |
| Median household income B19013 | $97,465 | $127,229 | $99,122 |
| Median family income B19113 | $109,115 | $148,679 | $113,346 |
| Per capita income B19301 | $41,008 | $62,927 | $49,513 |
| Poverty rate B17001 | 11.4% | 8.4% | 12.0% |
| Unemployment rate B23025 | 7.4% | 6.5% | 6.6% |
| Civilian labor force B23025 | 60,709 | 608,620 | 20,068,466 |
| Mean commute (minutes) B08013 | 42.0 | 35.3 | 28.7 |
| Bachelor's degree or higher B15003 | 23.9% | 45.2% | 37.1% |
| Housing units B25001 | 38,629 | 429,260 | 14,644,735 |
| Owner-occupied B25003 | 63.6% | 68.0% | 55.9% |
| Renters B25003 | 36.4% | 32.0% | 44.1% |
| Median home value B25077 | $629,700 | $866,800 | $734,700 |
| Median gross rent B25064 | $2,278 | $2,375 | $2,036 |
| White, not Hispanic B03002 | 23.4% | 38.1% | 33.8% |
| Black B03002 | 18.2% | 7.9% | 5.2% |
| Hispanic or Latino B03002 | 35.6% | 27.6% | 40.2% |
| Asian B03002 | 13.9% | 18.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.
Comments